HSBC Holdings
DSGN icon

HSBC Holdings’s Design Therapeutics DSGN Stock Holding History

HSBC Holdings’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,287
Closed -$168K – 3126
2024
Q3 		$168K Sell
31,287
-13,183
-30% -$62K ﹤0.01% 2682
2024
Q2 		$146K Sell
44,470
-4,319
-9% -$16.8K ﹤0.01% 2650
2024
Q1 		$197K Buy
48,789
+3,734
+8% +$9.97K ﹤0.01% 2691
2023
Q4 		$118K Buy
45,055
+8,565
+23% +$19.6K ﹤0.01% 2575
2023
Q3 		$85.6K Buy
+36,490
New +$170K ﹤0.01% 2572

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HSBC Holdings's DSGN Position: Q4 2024 in Review

HSBC Holdings sold out of Design Therapeutics (DSGN) in Q4 2024, closing a stake of 31,287 shares — an estimated $168K sold.

HSBC Holdings first reported a position in DSGN in Q3 2023 and held it in 5 quarters. The position peaked at $197K in Q1 2024. 95 funds tracked by Wall St. Rank hold DSGN as of Q4 2024.

  • HSBC Holdings reported no remaining Design Therapeutics position as of Q4 2024 after selling out during the quarter.
  • HSBC Holdings sold 31,287 Design Therapeutics shares in Q4 2024, an estimated $168K.
  • HSBC Holdings first reported a position in Design Therapeutics in Q3 2023 and held it in 5 quarters.
  • HSBC Holdings's Design Therapeutics position peaked at $197K in Q1 2024.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2024.

Based on HSBC Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.